Pyxis Oncology Elects New Directors at Annual Meeting

Pyxis Oncology ( (PYXS) ) just unveiled an announcement.

On June 18, 2025, Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in a virtual format. During the meeting, stockholders elected Dr. Santhosh Palani, Mr. Darren Cline, and Dr. Rachel Humphrey as Class I directors, whose terms will last until the 2028 Annual Meeting. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are expected to influence the company’s governance and financial oversight in the coming years.

The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.

Spark’s Take on PYXS Stock

According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.

Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.

To see Spark’s full report on PYXS stock, click here.

More about Pyxis Oncology

Pyxis Oncology, Inc. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in the research and development of novel therapeutics aimed at treating various forms of cancer.

Average Trading Volume: 475,091

Technical Sentiment Signal: Hold

Current Market Cap: $74.96M

For an in-depth examination of PYXS stock, go to TipRanks’ Overview page.